Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation
Blood Research
;
: 55-57, 2013.
Article
in English
| WPRIM
| ID: wpr-132573
ABSTRACT
Tacrolimus is a widely used immunosuppressive agent for the prophylaxis of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation (HSCT). Since tacrolimus is primarily metabolized by the liver, hepatic dysfunction may affect its metabolism. Hepatic veno-occlusive disease (VOD) is an early complication of HSCT that results in hepatic dysfunction, suggesting that VOD may affect tacrolimus metabolism. We report a case of hepatic VOD accompanied by a sustained high blood trough level of tacrolimus despite its discontinuation. The findings of this case suggest that the elimination of tacrolimus can be markedly delayed in patients with hepatic VOD, and that the clinician should carefully modulate the drug dosage for these patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Hepatic Veno-Occlusive Disease
/
Hematopoietic Stem Cells
/
Tacrolimus
/
Hematopoietic Stem Cell Transplantation
/
Graft vs Host Disease
/
Liver
Limits:
Humans
Language:
English
Journal:
Blood Research
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS